Literature DB >> 27558498

Roles of different IRES-dependent FGF2 isoforms in the acquisition of the major aggressive features of human metastatic melanoma.

Elena Andreucci1, Francesca Bianchini1, Alessio Biagioni1, Mario Del Rosso1, Laura Papucci2, Nicola Schiavone3, Lucia Magnelli1.   

Abstract

Fibroblast growth factor 2 (FGF2) is involved in many physiological and pathological processes. Fgf2 deregulation contributes to the acquisition of malignant features of melanoma and other cancers. FGF2 is an alternative translation product expressed as five isoforms, a low-molecular-weight (18 KDa) and four high-molecular-weight (22, 22.5, 24, 34 KDa) isoforms, with different subcellular distributions. An internal ribosomal entry site (IRES) in its mRNA controls the translation of all the isoforms with the exception for the cap-dependent 34 KDa. The 18-KDa isoform has been extensively studied, while very few is known about the roles of high molecular weight isoforms. FGF2 is known to promote melanoma development and progression. To disclose the differential contribution of FGF2 isoforms in melanoma, we forced the expression of IRES-dependent low-molecular-weight (LMW, 18 KDa) and high-molecular-weight (HMW, 22, 22.5, 24 KDa) isoforms in a human metastatic melanoma cell line. This comparative study highlights that, while LMW isoform confers stem-like features to melanoma cells and promotes angiogenesis, HMW isoforms induce higher migratory ability and contribute to tumor perfusion by promoting vasculogenic mimicry (VM) when endothelial cell-driven angiogenesis is lacking. To conclude, FGF2 isoforms mainly behave in specific, antithetical manners, but can cooperate in different steps of tumor progression, providing melanoma cells with major malignant features. KEY MESSAGE: FGF2 is an alternative translation product expressed as different isoforms termed LMW and HMW. FGF2 is involved in melanoma development and progression. HMW FGF2 isoforms enhance in vitro motility of melanoma cells. LMW FGF2 confers stem-like features and increases in vivo metastasization. LMW FGF2 promotes angiogenesis while HMW FGF2 induces vasculogenic mimicry.

Entities:  

Keywords:  FGF2 isoforms; Melanoma; Metastatic features; Vasculogenic mimicry

Mesh:

Substances:

Year:  2016        PMID: 27558498     DOI: 10.1007/s00109-016-1463-7

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  45 in total

Review 1.  Angiogenesis Revisited: An Overlooked Role of Endothelial Cell Metabolism in Vessel Sprouting.

Authors:  Saar Vandekeere; Mieke Dewerchin; Peter Carmeliet
Journal:  Microcirculation       Date:  2015-10       Impact factor: 2.628

Review 2.  Functional diversity of FGF-2 isoforms by intracellular sorting.

Authors:  Vigdis Sørensen; Trine Nilsen; Antoni Wiedłocha
Journal:  Bioessays       Date:  2006-05       Impact factor: 4.345

3.  VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.

Authors:  Jeanette Woolard; Wen-Ying Wang; Heather S Bevan; Yan Qiu; Lucia Morbidelli; Rowan O Pritchard-Jones; Tai-Gen Cui; Marto Sugiono; Elizabeth Waine; Rachel Perrin; Rebecca Foster; Jonathon Digby-Bell; Jacqueline D Shields; Cheryl E Whittles; Rosey E Mushens; David A Gillatt; Marina Ziche; Steven J Harper; David O Bates
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

4.  Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.

Authors:  F Yang; D W Strand; D R Rowley
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

5.  In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2.

Authors:  D Ribatti; D Leali; A Vacca; R Giuliani; A Gualandris; L Roncali; M L Nolli; M Presta
Journal:  J Cell Sci       Date:  1999-12       Impact factor: 5.285

Review 6.  Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?

Authors:  Piet Borst
Journal:  Open Biol       Date:  2012-05       Impact factor: 6.411

7.  Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.

Authors:  Maria Vinci; Sharon Gowan; Frances Boxall; Lisa Patterson; Miriam Zimmermann; William Court; Cara Lomas; Marta Mendiola; David Hardisson; Suzanne A Eccles
Journal:  BMC Biol       Date:  2012-03-22       Impact factor: 7.431

Review 8.  Epidemiology of invasive cutaneous melanoma.

Authors:  R M MacKie; A Hauschild; A M M Eggermont
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

9.  IRESite--a tool for the examination of viral and cellular internal ribosome entry sites.

Authors:  Martin Mokrejs; Tomás Masek; Václav Vopálensky; Petr Hlubucek; Philippe Delbos; Martin Pospísek
Journal:  Nucleic Acids Res       Date:  2009-11-16       Impact factor: 16.971

10.  DEspR roles in tumor vasculo-angiogenesis, invasiveness, CSC-survival and anoikis resistance: a 'common receptor coordinator' paradigm.

Authors:  Victoria L Herrera; Julius L Decano; Glaiza A Tan; Ann M Moran; Khristine A Pasion; Yuichi Matsubara; Nelson Ruiz-Opazo
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more
  2 in total

Review 1.  More than just scanning: the importance of cap-independent mRNA translation initiation for cellular stress response and cancer.

Authors:  Rafaela Lacerda; Juliane Menezes; Luísa Romão
Journal:  Cell Mol Life Sci       Date:  2016-12-02       Impact factor: 9.261

2.  LNC473 Regulating APAF1 IRES-Dependent Translation via Competitive Sponging miR574 and miR15b: Implications in Colorectal Cancer.

Authors:  Huizhe Wu; Xiaoyun Hu; Yalun Li; Qiuchen Chen; Tong Sun; Yun Qiao; Wenyan Qin; Zhikun Wu; Boshi Fu; Haishan Zhao; Rui Zhang; Minjie Wei
Journal:  Mol Ther Nucleic Acids       Date:  2020-07-10       Impact factor: 8.886

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.